9. Prioritize integration of systems and device-sharing across HIV and TB programs, including mapping of systems and diagnostic network optimization.
10. Work with Ministries of Health to improve and expand case-finding strategies and focus on priority entry points and index testing.
11. Incorporate LF-LAM and CrAg testing for infants and children with advanced HIV disease.
42. Support POC EID as well as case-finding through enhanced testing in inpatient, TB, and nutrition wards through the development of clear policies as well as program and operational guidance, and through implementation support.
43. Promote broader uptake of new sample types for laboratory systems and multiplex testing to improve cost efficiencies.
44. Invest in data management to provide more visibility to optimized laboratory networks for faster corrective actions and better quality testing.
45. Support Country Governments with 1) the latest data on performance and regulatory status of new diagnostics; 2) implementation of global guidance on product approvals and post market surveillance; and 3) once the WHO Collaborative Procedure for IVDs is established, promote rapid adoption, shifting the focus of quality assurance to post-market instead of pre-market.
46. Support the development of programmatic and operational guidance on POC VL for children, adolescents, and pregnant and breastfeeding women including by building evidence to support these policies.
Commitment 45: Launched an online Diagnostics Evidence Hub (https://aslm.org/diagnostic-hub/) hosted by African Society for Laboratory Medicine (ASLM) that serves as a repository for technical and performance data on WHO-prequalified, innovative diagnostics including Point-of-Care devices and HIV self-tests. This resource will allow country stakeholders to more easily access prior evaluations and validations to expedite in-country registration and scale up of innovative diagnostic technologies. Information hosted on the hub will include intended use, WHO PQ details and links to PQ reports, and summarized and linked data from relevant peer-reviewed studies and abstracts, including performance evaluations and feasibility studies. Under FASTER, CHAI will continue to work with ASLM and WHO to socialize the Diagnostics Evidence Hub through virtual meetings and webinars.
Working with CRS on in-country registration processes; building a consolidated database on paediatric diagnostic guidelines and technical evaluations with WHO and ASLM.
9. Advance the field of research in collaboration with Monell, MMV, and donors to identify a universal bitter blocker that can be used in pediatric formulations to improve palatability.
56. Through the Unitaid Optimal grant, accelerating access to optimal pediatric ARVs for children, including DTG 10 mg dispersible tablets, across focal countries.
57. With the support of Unitaid, support catalytic procurement of generic DTG 10 mg dispersible tablets across several focal countries to rapidly bring this optimal product to children by late Q1 2021.
32. Collaborate with WHO to house and incubate the GAP-f partnership through its start-up phase.
Commitment 32: With CRS’s support of CHAI through the FASTER grant, CHAI has been able to engage with multiple GAP-f partners to establish the consortium as a formal WHO network; expand the scope of diseases that GAP-f will be focusing on beyond HIV, TB and Hep C; and identify and convene an advisory committee for GAP-f to assist in strategic decision-making and fundraising.
3. (individual commitment) CHAI will commit full-time staff to assist EGPAF, WHO, PEPFAR, UNITAID and others to develop, coordinate and implement a detailed work plan to achieve the goals of the initiative; to assist with reaching agreements with companies, governments, donors and regulators to accelerate the introduction of optimal formulations and diagnostics for children and adolescents both short term and long term; and to work with governments and faith based organizations to scale up identification and treatment of HIV infected children and adolescents in the target countries.
CHAI has developed draft plans to accelerate in-country uptake of new pediatric ARVs in collaboration with other stakeholders.
Update on pediatrics DTG: All activities are on track including confidential, official correspondence with the FDA regarding the filing strategy for the DTG 10 mg scored DT.
CHAI is implementing the FASTER project under the leadership of Catholic Relief Services, funded by PEPFAR through CDC. This is an initiative between government, civil society organizations, FBOs and others to catalyze progress towards achieving 95-95-95 targets for children and adolescents. FASTER is being implemented in Nigeria, Uganda, Tanzania, Zambia, and Zimbabwe. The project focuses on 6 priority actions across the pediatric and adolescent testing and treatment cascade, agreed upon by a core set of stakeholders as a follow up to the 2017 Rome Action Plan. FASTER has also supported early GAP-f activities through support to the secretariat and expects to continue doing so until FY’21.